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Abstract
There is a poor relationship between nutrient intake and existing nutritional biomarkers due
to variety of factors affecting their sensitivity and specificity. To explore the impact of nutrients at
molecular level and devising a sensitive biomarker, proteomics is a central technology with sirtuins
as one of the most promising nutritional biomarker. Sirtuins (seven mammalian sirtuins reported so
far), have been reported to perform protein deacetylases and ADP-ribosyltransferases activity. It is
distributed  in  different  cellular  compartments  thereby  controlling  several  metabolic  processes.
Sirtuins are NAD+ dependent which implicates a direct effect of the metabolic state of the cell on its
activity. Calorie restriction upregulates the mammalian sirtuin protein levels in variety of tissues and
organs where it acts upon both histone and nonhistone substrates. Sirtuin senses nutrient availability
and  impacts  gluconeogenesis,  glycolysis  and  insulin  sensitivity.  It  deacetylates  and  inhibits  the
nuclear receptor that activates fat synthesis and adipogenesis in the body, leading to fat loss and
bringing  favorable  cellular  and  health  changes.  Sirtuins  mediates  intracellular  response  that
promotes cell survival, DNA damage repair thereby increasing the cell longitivity. The activation of
sirtuins  brings a wide spectrum of other  health  benefits  and its  activity  levels  are  indicative  of
nutritional  status as well  as disease progression in cancer,  inflammation,  obesity,  cardiovascular
diseases,  and  viral  infections.  There  are  several  foods  that  activate  sirtuin  activity  and  offer
significant health benefits by their consumption. 
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Introduction
Nutritional  epidemiology  depends  on  accurate  dietary  information  so  as  to  investigate
associations between diet and disease. Most popular dietary assessment tool is self-reporting through
questionnaire  which  is  highly  subjective  and  prone  to  bias  in  form  of  over  or  under  reporting.
Biological markers (biomarkers) on the other hand are objective, unbiased, overcome intra individual
diet variability (Hedrick et al., 2012) and helps to obtain a more proximal and integrated assessment of
nutrient status (Potischman, 2003). Hulka (1993) has defined biomarker as “cellular, biochemical or
molecular alteration that is measurable in biological media such as human tissues, cells, or fluids.”
Biomarkers can be understood as surrogate endpoints in clinical studies that may be used to predict
future  events.  Nutritional  biomarkers  are  indicators  of  dietary  exposure  and  indicate  past  dietary
intakes. The main reasons for using biomarkers are to achieve higher precision over memory based
dietary  assessment  (Kaaks  et  al.,  1997)  because  they  are  standardized  in  clinical  and  laboratory
practices (Don and Kaysen, 2004). They are of two main classes: recovery biomarkers (based on the
total  excretion  of  the  marker  over  a  defined time period  as  urinary  nitrogen and potassium)  and
concentration  biomarkers  (based  solely  on  the  concentration  of  the  respective  marker;  with  no
knowledge or details about the physiological balance of intake and excretion)  (Combs et al., 2013;
Kuhnle, 2012). Nutritional research has established several biomarkers for nutrients and food items as
indicated in Table-1. 
Determination of the human nutritional status is an important component to understand the
physiologic health of a person (Alp Ikizler, 2012) . An exemplary nutritional marker should quickly
acknowledge the variations caused owing to consumption of nutrients, be unaffected by presence of
other diseases, must be easily and accurately tested with easily available equipment in the hospitals,
and should be affordable for the patients.  Further, the biomarker must have the attributes as short
biological half-life, occur in a proportionately tiny pool, have a catabolic rate which can be foreseen,
and should be sensitive to specific nutrient intake. The present review is dedicated to identify, explore
and establish sirtuin, a NAD + dependent deacetylase, as a promising sensitive and specific proteomic
biomarker for determining the human nutritional status.  
Popular nutritional biomarkers
We begin with a bird’s eye view on the popular nutritional biomarkers and discussing their
degree of suitability to ascertain nutritional status. In the past, the circulating concentration of albumin
had been the most accepted nutritional biomarker and was considered as the most trusted agent to
reveal the nutritional status of a person. However, they are predominantly unresponsive to changes in
nutrient ingested, due to comparably vast body pool, which may require a fortnight to return to normal
levels  if  the  pool  has  been affected  (Spiekerman,  1995).  It  has  a  long half-life  (20 days)  and is
influenced by patient’s hydration status and consequently the renal functions  (Beck and Rosenthal,
2002). Besides, serum albumin levels are not a good choice of biomarker for elderly.  In geriatric
population, even without any inflammation, the albumin levels are reported to be elevated (Kuzuya et
al.,  2007).  Also  certain  physiological  stresses  exerted  during  dehydration,  marasmus,  blood
transfusions,  liver  failure,  instances  of  inflammation,  infection  or  metabolic  stress,  nephrotic
syndrome,  burns  and trauma etc.  has  been  observed  to  influence  the  circulating  levels  of  serum
albumin (Spikerman, 1995; Banh, 2006).
Transthyretin  was later  termed  as  prealbumin  (or  thyroxine-binding prealbumin)  since  it
moved more rapidly than albumin on electrophoresis. It is a circulating transport protein also reported
in cerebrospinal fluid. It carries thyroxine (T4) hormone and retinol-binding protein conjugated with
retinol. Serum prealbumin has been reported to have a shorter half-life (2.5 days) than albumin but the
levels of prealbumin increases with severe renal failure and consumption of corticosteroids and oral
contraceptives. The serum concentration of prealbumin depletes with liver disease, hepatitis, dialysis,
hyperthyroidism, pregnancy, hyperglycemia and inflammation. In the inflammatory state, its synthesis
lowered  being  a  negative  acute-phase  protein  (Gibson,  2005),  thus  we  understand  the  relative
insensitivity of prealbumin as a nutritional biomarker.
Banh (2006) observed that C-reactive protein (CRP) is a comparatively rapid marker (half-
life-19 hours) in comparison with previously discussed biomarkers namely albumin and prealbumin. It
is a choicest biomarker for inflammation. CRP substantiates the reliability of prealbumin marker and
generally is used along with prealbumin. Even though CRP is significantly sensitive to inflammations,
there  is  a  considerable  inter-individual  variability  which  is  highly  undesirable.  Its  concentration
(normal value- 10 mg/L) in healthy adults, may rise up to a 1000-fold in response to an inflammatory
stimulus and the degree of increase varies from patient to patient. This variability may be detrimental
to the diagnostic  reliability  of CRP  (Reny et  al.,  2002). Other factors as low grade inflammatory
processes,  dietary  and  behavioral  influences  and  cardiovascular  and  non-cardiovascular  medical
conditions are associated with an increase in CRP levels. The concurrent use of CRP as a promising
nutritional indicator has also not been substantiated.
Transferrin and retinol binding protein have also been identified as biomarkers of nutritional
status.  Transferrin  has  a  long biological  half-life  (8–10 days)  while  retinol  binding protein  has  a
significantly  short  half-life  (12 hours).  Transferrin  is  involved in  iron transport  and its  levels  are
influenced by existing iron status. Thus, iron deficiency may trigger rise in transferrin levels resulting
in increased iron absorption and therefore, it is often used as an indirect method for determining total
iron binding capacity. Hence this biomarker is greatly affected by intrinsic iron levels. Retinol binding
protein levels are dependent on the concentration of Vitamin A and zinc. Low levels of these two
nutrients  inhibit  mobilization of retinol  binding protein in the liver.  In the state  of kidney failure
owing to significant elevation of these two nutrients, the reliability and sensitivity of this marker is
greatly lost (Gibson, 2005).
We can now conclude that there is a poor relationship between serum protein levels and
nutrition status. Poor intake of nutrients does not consistently correlate with decrease in biomarkers as
albumin, prealbumin, transferrin, and retinol binding proteins. Also, an increasing intake necessarily
does not increase their levels. In light of these disparate results, it would be apt to conclude that serum
proteins are neither  specific,  nor sensitive indicators  of nutritional  status. As negative acute-phase
reactants,  the  concentrations  of  these  proteins  are  affected  by  the  acute  phase  response  (during
inflammation) and have been shown to be inversely associated with CRP. Many other extrinsic and
intrinsic factors also affect the concentration of these proteins. Therefore, there exists the dearth of a
nutritional biomarker that is specific, sensitive and unaffected by other disease conditions. 
Proteomic biomarkers
Every nutritional process depends on the interplay of a very large number of proteins that are
expressed  at  the  level  of  the  cell,  organ  or  the  whole  organism.  The  potential  importance  of
proteomics  for  the  nutritional  sciences  has  been  well  recognized  and  accepted.  Dietary
prevention/management of diseases, biomarkers and individualized requirements of nutrients are the
most recent, yet very crucial dimension that explains role of proteomics in nutritional sciences (Wang
et al.,  2006). A proteomic biomarker is defined as a specific peptide or protein associated with a
specific condition, such as the onset, manifestation, or progression of a disease or a response to the
treatment  (Mischak et al., 2010). It is well established that proteomics can be used to identify the
entire  protein  complement  of  a  cell,  tissue,  or  microorganism  at  different  stages  of  growth  and
development,  as  well  as  to  examine  the  integrated  response  to  a  particular  intrinsic  (hormonal,
nutritional)  or  extrinsic  (environmental)  challenge.  Thus,  we  propose  that  one  of  the  major
applications of proteomics may lie in the identification of degenerative disorders at the protein level,
during very early stage of disease initiation (Andersen et al., 1997; Trayhurn P, 2000; Fuchs et al.,
2005). 
The utilization of proteomics in nutritional research includes comprises of dimensions that
identifies  the  composition  and  characteristics  of  proteins  ingested,  that  is  further  detailed  by
digestion and absorption of nutrients in the gastrointestinal tract. Advanced proteomics research
investigates nutrient metabolism (synthesis and catabolism) and regulation, transport of nutrients,
tissue-specific  metabolism of  nutrients,  role  of  phytochemicals  in  growth,  signal  transduction,
cellular  defense  against  oxidative  stress,  cell  proliferation,  differentiation,  apoptosis  and  gene
expression in  response to  nutrients  and other  dietary  factors  (which may impact  absorption of
nutrients  in  the  body)  (Wang  et  al.,  2006).  The  application  of  proteomics  requires  access  to
specialized equipment and skills and expertise to operate it. Proteomics has the advantage over
cDNA micro-arrays of quantifying the functional  product (protein) of the gene expression,  and
allows identification of certain modifications that may relate to the activation or inactivation of
proteins by dietary interventions. Such circulating proteins play a major physiological role in target
organs, and also successfully reflect the changes in mechanisms initiated by dietary changes (de
Roos and McArdle, 2008). The classical two-dimensional (2D) gel electrophoresis coupled with
spot  analysis  by mass  spectrometry,  is  still  one of  the  most  widely  used proteomic  technique
utilized to identify changes in the individual proteins of tissues, cells and bio-fluids due to dietary
changes (Fuchs, 2005).This approach not only identifies individual proteins but also reveals the
rate of metabolic turnover. However it is not reliable technique to visualize and detect differential
regulation of low concentration proteins. Also, very hydrophobic, acidic or basic proteins cannot be
accurately detected by this method (Gygi et al., 2000). Moreover, this method is labour intensive
(de Roos and McArdle, 2008) and significantly uneconomical. Therefore, 2D gel electrophoresis
may not always represent the most sensitive tool to reveal effects of nutritional interventions on
inflammatory pathways.
    Nutritional science is at a transactional stage. In past, the nutritional science primarily focused
on identification of essential nutrients and understanding their biological importance in maintaining
health,  but today it  significantly focuses at  health  promotion,  disease prevention and performance
improvement. This is accomplished by studying the pattern of overall composition of the diet, the
levels of specific nutrients and non-nutrient components of foods and many other aspects of lifestyle
that affects the flow of genetic information from gene expression to protein synthesis and protein
degradation. For the nutritional scientist, this information is of special interest in studying the diseases
where diet plays an important role. 
Nutritionists generally encounter challenges as they seek to understand the impact of nutrients at
the molecular level. As a result there exists a vital scope to establish proteomics in field of nutrition.
Proteomics is a central technology in post-genomic nutritional research for assessing the effects of diet
composition,  specific  nutrients  and  non-nutrient  components  on  the  genome  and  on  mammalian
metabolism. And if the nutrition science has to match the advances of other branches of biology in the
post-genomic  era,  it  must  utilize  proteomic  biomarkers  to  assess  minutest,  yet  crucial  aspects  of
human nutrition (Fuchs et al., 2005). 
Noteworthy  are  the  families  of  Silent  Information  Regulators  (SIR)  that  encodes  for  genes
which promote body's defenses during physiological stress like calorie restriction. The genes from this
family  have  been  well  documented  and studied  to  significantly  maintain  health  and prolong  life
expectancy in  wide variety  of organism ranging from bacteria  to  mammals.  Biochemically,  SIR2
removes  acetyl  tags  from the  histones,  but  interestingly  its  enzymatic  activity  requires  oxidized
nicotinamide adenine dinucleotide (NAD+). Now NAD+ has been already known as a participant and
key regulator of many metabolic reactions in cells. Due to an association between SIR2 and NAD+,
SIR2  activity  modulates  multiple  biological  processes  particularly  associated  with  metabolism
(metabolic  redox reactions),  DNA repair  etc.  Hence  this  association  potentially  links  the  relation
among  diet  and several  diseases  and even  ageing.  Sirtuins  are  members  of  the  sirtuin  family  of
proteins, homologs of the Sir2 gene. We will now undertake an in depth understanding designed to
point at the potential of sirtuins as an ideal nutritional biomarker.
NAD+-dependent cellular deacetylases as emerging nutritional biomarkers
Sirtuins has been a subject of considerable interest and excitement as an important biomarker
in ageing biology ever since it was discovered in late 1990’s. Sirtuins were initially referred to as
evolutionarily conserved NAD+ dependent class III histone deacetylases (HDAC) implicated in
several  age  related  degenerative  diseases  such  as  cancer,  diabetes,  cardiovascular  disease  and
neurodegenerative  disorders  (Tao et  al.,  2010).  Consequently,  it  was  observed that,  apart  from
histones, sirtuins also are capable to deacetylate several regulatory protein, structural protein and
catalytically active proteins as key substrates, thereby revealing their ability to utilize wide range of
substrates  (Martínez-Redondo  and  Vaquero,  2013).  They  are  extensively  reported  and  well
established as NAD+ dependent deacetylases/deacylases and ADP-ribosyltransferases, that couple
protein deacetylation of histone and non-histone substrates with the energy state of the cell (the
cellular NAD+/NADH ratio) (Schwer and Verdin, 2008). This yields a highly regulated proteome
with more than 4000 acetylated proteins in the tissues of experimental rats (Lundby and Olsen,
2012) (Fig- 1).
It has been scientifically proven that nearly all  enzymes of glycolysis, gluconeogenesis,
glycogen metabolism, fatty acid oxidation, nitrogen metabolism, tricarboxylic acid (TCA) cycle,
and  oxidative  phosphorylation  are  abundantly  acetylated  (Zhao  et  al.,  2010) along  with  the
frequent  conservation  of  acetylation  sites  across  diverse organisms  (Choudhary et  al.,  2014).
Several  published reports  have  indicated  that  sirtuins  are  virtually  ubiquitous  throughout  the
kingdoms  of  life.  It  is  reported  to  be  present  from bacteria  to  eukaryotes.  The  first  NAD+
dependent  deacetylases  namely  SIRT2  was  reported  in  the  budding  yeast  (Saccharomyces
cerevisiae) (Frey, 1999; Frey, 2000; Greiss and Gartner 2009). So far seven mammalian sirtuins
have been identified and their distribution is throughout the cellular compartments. This explains
the  diversity  and  complexity  in  their  cellular  localization  and functions  (Fyre,  2000;  Moris,
2013).  Substantial  evidences  on  association  between  sirtuins  and  disease  conditions  such  as
diabetes,  metabolic  diseases,  cardiovascular  diseases,  neurodegenerative  diseases  and  cancers
have been reported in mostly animal models (Haigis and  Sinclair, 2010;  Guarente, 2014). The
composite families of sirtuins contain approximately 260 amino acids which have a high degree
of sequence similarity. This family has been further divided and categorized into five different
classes namely I, II, III, IV and U. The division based of phylogenetic analysis of more than sixty
sirtuins  which  were  obtained from variety  of  organisms.  The human genome encodes  seven
sirtuins which are categorized in the classes from I to IV; while the U-class sirtuins are reported
only in Gram-positive bacteria (North et al., 2003). 
Michishita  et  al.  (2005a) has documented that  all  the known seven mammalian sirtuins
(SIRT1-7)  show dynamic  intracellular  localization  and deacetylate  different  sets  of  substrate
proteins. Michan and Sinclair (2007) and Zhang and Kraus (2010) observed that SIRT1 positions
in the nucleus (Euchromatin) and regulates metabolic processes of transcription factors such as
p53 and PGC-1α.  North et al. (2003) reported that location of SIRT2 is mainly in the cytosol
where it deacetylates α- tubulin. The biological activities of SIRT1 and SIRT2 have been most
extensively studied due to the enormous significant metabolic activities attributed to both of these
(Li and Kazgan, 2011). The mitochondria  are reported to contain SIRT3, SIRT4, and SIRT5
(Girtz and Steegborn, 2010). SIRT 6 occurs in heterochromatin and deacetylates histones and
regulates DNA stability and repair (Michishita  et al., 2005 b; Kaidi, 2010). SIRT3 regulates a
large set of metabolic enzymes while SIRT6 and SIRT7 are nuclear isoforms. SIRT7 has been
reported to monitor the activity of RNA polymerase (Ford et al., 2006) and to deacetylate p53
(Vakhrusheva et  al.,  2008),  thereby exhibiting a crucial  role  in  various  types of cancers  and
identifying SIRT7 as one of the promising cancer drug targets (Priyanka et al., 2016). 
SIRT1 has a decisive role in glucose homeostasis and lipid metabolism in various tissues
as  adipose,  liver,  pancreas,  and  skeletal  muscle  (Kume  et  al.,  2010).  Manifold  studies  have
reported that  SIRT1 and SIRT3 share the common attribute  of significant  tumor suppression
activity (Bell et al., 2011; Finley et al., 2011; Herranz et al., 2010; Herranz and Serrano, 2013).
SIRT4  is  the  only  mammalian  sirtuin  without  a  reported  deacetylation  substrate.  Instead  of
deacetylation SIRT4 performs ADP-ribosylation, which is a second type of reaction that can be
catalyzed by sirtuins through utilizing glutamate dehydrogenase  (Haigis et al., 2006). There is
only one physiological substrate known for SIRT5, namely- carbamoylphosphate synthetase I
(Hirschey et al., 2011) (Table- 2). 
With such reports, there is a spontaneous central question that can sirtuins promote health
against ageing associated diseases? Are these proteins important for mediating anti-ageing effects
of a low-calorie diet? How calorie restriction impacts their activity? Do they have any role in
expanding  life  span of  organisms? And most  importantly  how can sirtuin  be an  appropriate
nutritional biomarker? In the following section, we will explore role of sirtuin in metabolism to
address the questions raised above.
Role of sirtuin in metabolism
Sirtuins  are  major  regulators  of  a  variety  of  cellular  processes,  ranging  from  energy
metabolism, stress response, tumorigenesis and ageing. Hagis and Sinclair (2010) have reported that
SIRT1 is involved in hepatic gluconeogenesis, fat mobilization, and pancreatic insulin secretion. It
also regulates hepatic fatty acid oxidation. The activity of sirtuin is influenced by availability of
nutrients which is expressed as obesity-induced inflammation in macrophages and modulation of
activity of the circadian clock in metabolically active tissues. During fasting or calorie restriction,
there  is  negative  energy balance  and SIRT1 has  been reported  to  be  upregulated.  It  stimulates
gluconeogenesis and inhibits glycolysis (Nemoto et al., 2004; Nie et al., 2009; Rodgers et al., 2005;
Rodgers and Puigserver, 2007). In a cell, gluconeogenesis and glycolysis are highly coordinated and
well-regulated pathways. If one pathway is relatively inactive the other becomes active. Now both
glycolysis and gluconeogenesis are significantly exergonic under cellular conditions and there is no
thermodynamic barrier to regulate these two simultaneous activities. It is by the regulated activity of
distinctive enzymes for each pathway, that the two processes are controlled, resulting in only one
pathway being activated at a given time.  Rodgers et al. (2005) experimented that sirtuin promotes
this reciprocal regulation of the two pathways during negative energy balance through deacetylation
of PGC-1α, the transcriptional coactivator. It was also reported that SIRT1 deacetylates PGC-1α in a
NAD+ dependent manner (Picard et al., 2004; Nemoto et al., 2005; Rodgers et al., 2005; Liu et al.,
2012). Importantly,  the SIRT1 mediated regulation of PGC-1α was found to be essential  during
fasting or pyruvate-mediated increases in gluconeogenic genes (PEPCK and G6Pase) and glucose
output in cultured hepatocytes. Furthermore, this deacetylation also acts to decrease the expression
of glycolytic genes (glucokinase and LPK) (Rodgers et al., 2005). 
This stimulating effect of SIRT1 on hepatic glucose output during fasting was also confirmed
in mice (Rodgers and Puigserver, 2007; Erion et al., 2009). This finding signifies the putative role of
sirtuin as a marker of an important nutritional aspect namely hepatic glucose levels. 
SIRT1 may also act to regulate the hepatic glucose production during prolonged fasting (Liu
et al., 2012). Further, during negative energy balance, the liver mobilizes lipid and glycogen stores
into energy by β-oxidation of fatty acid and glycogenolysis or gluconeogenesis. Now SIRT1 inhibits
the early phase of glucogenogenesis by regulating the key mediator during short-term fasting (Li,
2008).  This implies that during negative energy balance,  there is  enhanced SIRT1 deacetylation
coupled with activation of PGC-1α along with the enhanced lipid catabolism. The consequence is
significantly improved fatty acid oxidation and enhanced glucose homeostasis (Purushottam et al.,
2009;  Dominy et  al.,  2010).  Alternatively,  in  the  well  fed  state,  when there  is  positive  energy
balance, the metabolic machinery aims towards storage of energy in form of glycogen in the liver.
Thus,  the  overall  influence  of  SIRT1  on  the  regulation  of  gluconeogenesis  is  decided  by  the
complex  multiple  interactions  among  factors  of  different  phases  of  negative  or  positive  energy
balance  (Li,  2013).  Liu  et  al.,  (2012) has  verified  that  as  a  result  of  increased  NAD+ during
glycolysis, there is SIRT1 mediated repressing of  PPARγa (transcription factor that regulates genes
of fat storage) and activation of PPARGC1B (transcription factor for mitochondrial biogenesis that
increases oxidative metabolism) leading to the metabolic transition from glycolysis to fatty acid
oxidation  (Fig-  2).  The  above  studies  help  us  understand  the  intricate  and  highly  dependent
intercellular interactions of transcription factors with SIRT1 that unanimously aim towards shift of
the metabolic process based upon the energy state of the cell. 
New  age  scientific  developments  in  agriculture  and  technologies  with  blooming  food
processing industries have promoted the intake of rich high-calorie diets and a sedentary lifestyle.
This leads to obesity, cardiovascular disorders, diabetes etc. In the obese individuals, excess adipose
tissue increases the levels of Nonestrified fatty acids (NEFA). These excess NEFA accumulates on
other  metabolic  tissues  such  as  liver,  muscle,  and  pancreatic  β-cells,  resulting  in  atherogenic
dyslipidemia,  insulin resistance, and hyperinsulinemia  (Schug et al.,  2010; Schug and Li, 2011).
Tarantino et al., (2014) have reported that in obese subjects (Body Mass Index above 30), a lowered
serum levels of SIRT4 was reported, indicative of inverse relationship between Body Mass Index
and circulating SIRT4. This observation has been established as a putative cause of risk factors for
coronary artery diseases such as low HDL, visceral obesity expressed as high weight/height ratio.
SIRT1 influences hepatic cholesterol and bile acid homeostasis. It operates by affecting the
nuclear receptors present in liver. Farnesoid X receptor (FXR) is the bile sensor which is targeted by
hepatic SIRT1 during the process of metabolic regulation (Purushottam et al., 2012). The signaling
pathway of SIRT1 and FXR mutually interacts and influences metabolism at multiple levels. As a
result, these two regulates the homeostasis between hepatic bile acid and cholesterol mobilization in
the body. Also, SIRT1 is supposed to regulate hepatic lipid metabolism through deacetylation of the
sterol regulatory element-binding protein (SREBP) (Ponugoti et al., 2010; Walker et al., 2010). To
unwind this mechanism, it must be highlighted that fasting (short-term food deprivation) produces
an  instant  metabolic  drift  from synthesis  of  lipids  and  cholesterol  to  their  mobilization.  When
intracellular lipids and cholesterol levels are high, SREBP precursors are tethered and restricted and
their  gene  transcription  is  activated  during  depletion  of  lipids  and  cholesterol  (Osborne  and
Espenshade 2009; Riu, 2014). Now these negative feedback mechanisms control the processing of
the  precursor  forms  of  SREBP  but  question  is  as  to  how  SREBP  are  controlled  by  nutrient
deprivation? There are no reports as to how nutrient deprivation triggers the SREBP family member
affecting the transcription in response to insulin signaling (Walker et al., 2010)? One attractive and
suitable candidate to initiate deacetylation of the SREBP family of transcription factors in response
to  nutrient  deprivation  is  SIRT1  (Guarente,  2006),  as  SREBP  proteins  are  required
for cholesterol and fatty  acid biosynthesis.  SIRT1  can  directly  deacetylate  SREBP  thereby
contributing to its  metabolic  regulation.  It  may be claimed that SIRT1 helps to improve insulin
sensitivity  in  obese  subjects  by  offering  a  protective  effect  against  obesity.  The  concept  that
activation of SIRT1 can result in loss of body fat without affecting the caloric intake  (Baur et al.,
2006) could open the door for novel treatment for obesity and related diseases (Fig-3).  Further,
sirtuin may be believed as a promising biomarker to reveal the nutritional status in terms of fat
accumulation and oxidation and its modulation will beneficially impact the storage and metabolism
of fat in the body.
The effect of sirtuin on overall metabolism is multidimensional and its metabolic functions
reveal that their effect on degenerative diseases is extremely crucial. Sirtuins influence the immune
system also by reducing inflammation in multiple tissues particularly macrophage (Schug  et al.,
2010),  while  the  reduction  of  SIRT1  in  hepatic  cells  caused  in  increased  local  inflammation
(Purushotham  et  al.,  2009).  Baur  et  al.  (2006)  revealed  that  a  mice  fed  a  high-fat  diet  when
administered with SIRT1, resulted in improved liver functions and metabolism. In a hyperglycemic
environment, SIRT1-mediated activation prevents lipid accumulation  (Hou et al., 2008). In fact in
the brain, SIRT1 functions as a potential link between the pituitary hormones and calorie restriction
longevity pathways in mammals  (Cohen et al., 2009). Many changes induced by SIRT1 activation
are related  to  increased  mitochondrial  metabolism and antioxidant  protection  in the  fasting  fish
(Simó-Mirabet et al., 2016). It is worth noting that SIRT1 overexpression downregulated the pro-
inflammatory genes in mice (Pfluger et al., 2008; Yoshizaki et al., 2010), while obesity with chronic
inflammation was associated with reduced levels of SIRT1 (Vachharajani et al., 2016). This finding
advocates  and  highlights  the  capability  of  sirtuin  as  a  biomarker  for  lipid  accumulation  led
inflammations in biological systems.
The members of sirtuin families being NAD+ dependent deacetylases, participate in many
cellular processes as cell proliferation,  senescence and stress response. They might play either a
promoting or suppressing role, depending on the organ or even the species.  Expression of SIRT1
increases in prostate cancer (Hauffman et al., 2007) and acute myelocytic leukemia (Bradbury et al.,
2005). An enhanced overexpression of SIRT1 in colonic tubular adenoma was observed and it was
advocated as a useful biomarker in the diagnosis of high grade dysplasia and invasive carcinoma
(Zhang and Wang, 2013). Aligning with them is the finding of Grbesa et al. (2015), who observed
that the activity of SIRT1 and SIRT2 protein was significantly increased in the cancer cell lines of
lungs as compared with non-tumor epithelial cells of the lungs. The expression of SIRT1 and SIRT2
proteins was also found to increase in tumor cells of lungs than normal lung cells.  These findings
even suggested that SIRT1 inhibitors may act as potential anti-cancer agents and that the potential
tumor suppressive effects of SIRT1 need to be kept in mind while considering SIRT1 inhibitors for
cancer treatment (Li et al., 2008). 
There  are  multiple  studies  that  demonstrated  that  the  possible  regulatory  mechanism of
SIRT1 on the cancer gene is associated with tumor protein p53 (Hishida et al., 2012). As we already
know that the p53 protein is a tumor suppressor protein. Its lowered expression or mutation leads to
enhanced risk of cancer (Muller and Vousden, 2013). Deacetylation of p53 by SIRT1 is reported to
play an important role in preventing p53 activation and thus promoting cancer cells (Brooks and Gu,
2010; Castro et al., 2013). This is how SIRT1 impacts the activity of p53 gene and gets highlighted
as a cancer promoting agent. But there is a considerable paradox in this regard. 
Several  contradicting  studies  have  indicated  that  the  p53 inactivation  by SIRT1 actually
promotes cell survival during stress (Luo et al., 2001) and that SIRT1 arrests p53 induced apoptosis
by p53 deacetylation and induction of manganese superoxide dismutase (MnSOD) (Tanno et al.,
2010; Tao et al., 2010). We need more research and insight to simplify exact reason and role of
increased SIRT1 status during cancer. Despite clear inhibitory effect of increased SIRT1 expression
on tumor suppressors like p53, other studies have suggested that SIRT1 may have tumor suppressive
functions as well. This can be partly explained by studies conducted by (Maiese et al., 2009) where
they observed that SIRT1 offers protection against oxidative stress through modulation of forkhead
transcription factors in some cells. While Hasegawa et al., (2008) observed that SIRT1 protects cells
against  oxidative  stress  by  increasing  the  activity  of  antioxidant  enzyme-  catalase.  The  calorie
restriction helps to combat oxidative stress through SIRT3-mediated enhancement of Super Oxide
Dismutase (SOD) activity (Qui et al., 2010). Also, SIRT1 overexpression increases the tolerance
against  free  radical  toxicity  in  neuronal  cells  (Chong and  Maiese,  2008). Howitz  et  al.  (2003)
studied about resveratrol which was reported to improve chances of cell  survival by stimulating
SIRT1- dependent deacetylation of p53.  
The expression and activation of SIRT1 can be influenced by several cellular conditions such
as calorie restriction, exercise and oxidative stress in the cell. SIRT1 uses NAD+ as a substrate, but
the level of NAD+ can also control the deacetylating activity of SIRT1. Moreover, the activity of
SIRT1 may depend on the cell process and cell type studied. So can it be justified to propose that
sirtuin  levels  increases  during  cancer  as  a  part  of  body’s  homeostasis  and  performs  protective
mechanism to fight against cancer and induce longitivity as sirtuins are genes for longitivity?  This
aspect of research is scattered with contradictions and bidirectional views, therefore it needs more
focus and insight to actualize the role of sirtuin in cancers. 
SIRT4 has been observed to modulate the metabolism of NEFA. The adipose tissues release
NEFA,  triggering  oxidative  stress  that  results  in  endothelial  dysfunction,  early  atherosclerosis,
culminating to risk factors of coronary artery disease (Tarantino et al., 2014). Lowering activity of
SIRT4 has been associated with an increased free fatty acid oxidation in liver and in muscle (Nasrin
et al., 2010). This finding indicates that an enhanced level of SIRT4 may qualify as an indicator of
better antioxidant status of the organism in terms of concentration of NEFA. (Wang et al., 2007) and
Calabrese et al. (2012) reported that sirtuin reduce the reactive oxygen species (ROS) by modulating
the acetylation of the respiratory chain, stimulating mitochondrial SOD and isocitric dehydrogenase
which generates NADPH for glutathione pathway. Such reports establish the significant antioxidant
potential  of  sirtuins.  Research  has  also  shown  that  SIRT5  plays  a  pivotal  role  in  ammonia
detoxification  (Nakagawa et al.,  2009).  (Michishita et al.,  2008) had observed that all  the seven
sirtuins are found in detectable limits in all human tissues, moreover the impact of sirtuin on most of
the tissues is traceable so we must ascertain the metabolomics performed by sirtuins and examine it
in detail.
NAD+ metabolism and sirtuins 
There is  widespread interest  in pharmacological  manipulation  of NAD+ because of their
evident  role  in  health  and disease  (Wang et  al.,  2015).  NAD+ is  synthesized  from vitamin B3
precursors,  mainly  nicotinamide  in  human beings.  Biochemically,  nicotinamide  is  also the  final
degradation  product  of  entire  NAD+ dependent  signaling  reactions. This  synthesis  requires  the
enzyme  nicotinamide  phosphoribosyltransferase  (NAMPT),  which  produces  nicotinamide
mononucleotide (NMN) from nicotinamide (NAM). NMN is then converted directly to NAD+ by
the  enzyme  nicotinamide  mononucleotide  adenylyltransferase  (NMAT).  In  our  body,  NAD+
mediated  signaling  processes  affect  the  control  of  fundamental  cellular  events  wherein  it  is  an
essential redox carrier.
     NAD+ dependent deacetylation by sirtuins is observed to affect the activity of proteins along
with its stabilization. This in turn regulates physiological process as ageing, transcription, apoptosis,
genome  stability,  mitochondrial  biogenesis  etc.  This  shows  how  sirtuin  influences  many  vital
processes in the body. As sirtuins utilizes NAD+ as a co-substrate, their activity must depend on the
bioenergetic state of the cell (which is, in part, reflected by the NAD+/ NADH ratio and the overall
NAD+  concentration).  It  implies  that  sirtuins  directly  link  the  metabolic  state  with  signaling
processes. Further they also regulate the cellular response as per the energy state of the cell and
associated environmental signals influencing it. 
Besides  deacetylase  activity,  sirtuins  also  perform  other  enzymatic  activities  such  as
ADP  ribosylation  (SIRT1,  SIRT4,  and  SIRT6),  desuccinylation  and  demalonylation  (SIRT5),
delipoylation  (SIRT4),  demyristoylation  and  depalmitoylation  (SIRT6)  (Martinez–Redondo  and
Vaquero, 2013). With this diverse spectrum of activities and localizations, it will be wise and apt to
label sirtuins as core regulators of transcription and metabolism. 
As  an  agent  of  ADP-ribosylation,  sirtuin  mediates  transfer  of  a  single  (mono-ADP-
ribosylation)  or several  (polyADP-ribosylation) ADP-ribose units  from NAD+ to specific  amino
acids of acceptor proteins. SIRT4 and SIRT6 are able to mono-ADP-ribosylate proteins (Mao et al.,
2011).  Intracellular  mono  and  poly  ADP-ribosylation  is  involved  in  many  essential  cellular
processes viz. DNA repair, apoptosis, transcription, cell cycle progression, energy metabolism and
many others  (Nikiforov et  al.,  2015). A recent metabolomics  study by  (Sadhukhan et al.,  2016)
indicated that different tissues have very different acyl-CoA profiles and succinylation of protein
lysine across different tissues was studied. The research findings suggested that succinylation of
lysine  predominantly  accumulates  in  the  heart  when  SIRT5 is  deleted.  ECHA (desuccinylation
substrate of SIRT5) is activated by SIRT5 as a result, SIRT5 deficient mice exhibited defective fatty
acid metabolism and decreased ATP production, thus implying a reduced cardiac function. Thus,
protein succinylation and SIRT5 noticeably exert an important role in cardiac function and heart
metabolism.  Acetyl-CoA  and  succinyl-CoA  are  important  intracellular  metabolites  involved  in
diverse metabolic pathways including the TCA cycle. The presence of two positively charged amino
acids (Tyr102 and Arg105) in the active site of SIRT5 justifies its preference for negatively charged
acyl groups such as succinyllysine. Also it has been already documented that SIRT1 is known to
affect Ischemic preconditioning (intrinsic process that protects myocardial tissues against ischemic
insults) (Hafner, 2010; Nadtochiy et al., 2015; Oellerich and Potente, 2012).
The horizon of SIRT1 removing the acetyl groups from lysine on histones residues, brings
into picture the possibility of SIRT1 linkage with viruses. Histones namely- H3K9ac, H3K14ac, or
H4K16ac are deacetylated by SIRT1, this in turn triggers the formation of heterochromatin, thereby
affecting the gene expression (Martinez–Redondoand and Vaquero el, 2013). Sirtuins impacts the
result  of  viral  infection  by  modulating  both  host  and  viral  gene  expression.  In  turn,  viruses
manipulate  the  host  epigenetic  and  transcription  machineries  by  overtaking  SIRT1  regulated
pathways.  This phenomenon is  observed in deacetylation of the human immunodeficiency virus
(HIV) protein – Tat, thereby enabling  HIV transactivation (Pagans et al., 2005). In hepatitis B virus,
in the cell lines expressing viral gene products, there is upregulation of SIRT1 mRNA and protein
(Ren et al., 2014). The same has been reported in influenza A virus (Koyuncu et al., 2014).
     Many deacetylases can influence important transcription factors but it is still ambiguous
that whether the impact of sirtuins is redundant or dependent on specific conditions. Also, sirtuins
can deacetylate histones on both viral and host chromatin, replicate both DNA and RNA virus, and
they exhibit wide diversity of substrates (both histone and nonhistone proteins). Therefore, there is a
scope of further research into the understand of mechanisms and explanations as to how both hosts
and viruses undergoes clashes to gain control over sirtuin activity to either inhibit or enhance the
further viral replication (Budayeva et al., 2016). Interestingly, the bacterial sirtuin (CobB) which is
structurally similar to mammalian sirtuins is reported to impact the growth certain bacteriophages
(Zhao et al., 2004); so can it be concluded that sirtuins have been the primitive antiviral defense
factors that  protected against a variety of pathogens? (Koyuncu  et al.,  2014).  How sirtuins link
cellular homeostasis to health and to understand the mechanism of action of sirtuin within the cell is
the forthcoming concern.
Sirtuins within the cell
 Fyre  (2000)  has  reported  that  all  the  seven  sirtuins  (SIRT1–7)  reported  in  humans  are
characterized by an evolutionarily conserved sirtuin core domain. This domain has been reported to
perform the catalytic  activity  and reported to  contain  invariant  amino acid residues  involved in
binding NAD+. As mentioned before, sirtuins exhibit NAD+ dependent protein deacetylase activity
and ADP ribosyltransferase activity. All sirtuins have been reported to have well defined acetylated
substrates except for SIRT4. It is observed that all seven sirtuins target distinct acetylated protein
substrates and are localized in distinct sub-cellular compartments. As already mentioned; SIRT1,
SIRT6 and SIRT7 occur in the nucleus, SIRT2 is mainly localized in cytosol while SIRT3, SIRT4
and  SIRT5  are  found  in  the  mitochondria.  SIRT1  and  SIRT3  have  been  identified  as  major
regulators of metabolic processes in mammals. They are localized in the nucleus and mitochondria,
respectively.  SIRT 1 and SIRT 3 deacetylates  a variety of proteins and improve cellular energy
stores and this is how they contribute in maintaining cellular energy homeostasis  (Hirschey et al.,
2011; Nogueiras et al., 2012). Localized in mitochondria are SIRT3, SIRT4 and SIRT5, which have
been studied and reported as agents who impact the activity of important mitochondrial enzymes
and guide the metabolic cycles accordingly to the energy state of the cell (Chalkiadaki and Guarente,
2012). As SIRT1 lacks a DNA-binding domain,  it  is subjected to target promoters by sequence
specific transcription factors so as to incorporate chromatin remodeling and subsequently regulation
of gene expression (Prozorovski et al., 2008). Also, SIRT1 is associated with the heterochromatin
regions where they promote deacetylation of histone (Vaquero et al., 2004). It can be inferred that
owing  to  multiple  molecular  functions  performed  by  SIRT1  namely  deacetylation,  epigenetic
modifications,  and transcription factor modulation;  SIRT1 can be potential  link between cellular
metabolic status and adaptive transcriptional responses (Bordone and Guarente, 2005). 
It  is  already  established  that  SIRT1  proteins  exert  their  effects  through  two  different
pathways namely histone modifications and nonhistone substrates. In histone modification, many
ageing related effects  are caused by chromatin changes.  Since SIRT1 is localised mainly in the
nucleus,  its  physiological  actions  are  partly  mediated  by  its  ability  to  deacetylate  nucleosomal
histones  at  specific  residues  (Pallàs  et  al.,  2008;  Miroslava  et  al.,  2014).  While  the  nonhistone
modification exhibits that once SIRT1 is activated it mediates intracellular responses that promote
cell survival, enhance the repair of damaged DNA, and reduce cell division. Experiments indicated
that for every acetyl lysine group that is removed, one molecule of NAD+ is cleaved, nicotinamide
and  O-acetyl-ADP-ribose  are  produced  (Harikumar  and  Aggarwal,  2008;  Rauh  et  al.,  2013).
Therefore,  SIRT1 appears to possess two enzymatic activities;  first the deacetylation of a target
protein and second the metabolism of NAD+. This distribution helps us to understand the underlying
mechanism attributed to sirtuin and its effect on health. In all living organisms, cellular energy is
produced and expended using universal “energy currencies” such as ATP and NADH. The tight
balance between such anabolic and catabolic pathways ensures that cells do not deplete essential
energy stores,  which would ultimately cause cellular  damage or death.  Sirtuins are significantly
involved in mammalian energy homeostasis (Nogueiras et al., 2012).
The  activity  of  SIRT1  is  highly  regulated  towards  the  environmental  factors  that  may
influence  it.  A  feeding  regime  that  is  reported  to  accelerate  the  sirtuin  activation  is  caloric
restriction, which corresponds to a lowering of 20% – 40% calories below ad libitum intake without
inducing malnutrition (Sumeya et  al,  2010; Lomb et al.,  2010). The levels  of sirtuin have been
reported to enhance in fasting mice (Kanfi et al., 2008). 
Much difference in opinion has been reported in context to understand how calorie restriction
can affect  the life  span (Zhao et  al.,  2010;  Li,  2013).  It  may be a  simple analogy that  nutrient
shortage  leads  to  increased  NAD+  levels,  improving  sirtuin  activity.  This  shows  how  calorie
restriction  improves  sirtuin  activity.  Sirtuins  are  obviously  nutrient  sensors  as  it  is  actually  the
nutrient availability which affects the ratio of NADH to NAD+ (Rodgers et al., 2005). Increase in
this  ratio  will  automatically  increase  sirtuins  levels.  Hagopian  et  al.  (2009)  and  Gambini et  al.
(2011)  have  already  established  that  the  calorie  restriction  results  in  an  increase  in  [NADH]/
[NAD+] levels resulting in increased sirtuin levels, thereby impacting the longevity. Laurent et al.
(2013) gave a concomitant report that genetic and pharmacological restoration of NAD+ levels not
only enhances sirtuin activity in experimental animals but consequently delays the ageing process.
Hence, there is an opportunity for preventive and/or therapeutic utilization of this mechanism in the
improving aspects related to ageing and related disorders. With many favorable physiological and
significant health attributes, we must explore and compare various prevailing and potential methods
to assay the activities of sirtuins in tissues.
Methods to assess sirtuin activity
The assay to  determine  levels/activity  of  sirtuins  has been successfully  accomplished by
different types of methods. Borra and Denu (2004) have reported that historically the radioactive
sirtuin assay uses the radioactive substrates. This technique monitors the transfer of a [3H]-labeled
acetyl  group  from  peptide  or  protein  substrate  to  the  [3H]  OAADPr  product  or  [3H]  acetate
hydrolyzed  from  [3H]OAADPr.  Later,  the  products  and  reactants  were  separated  using
chromatography,  ethyl  acetate  extraction,  or  charcoal  binding  followed  by  detection  under  the
scintillation  counter.  Alternatively,  release  of  [14C]-nicotinamide  from  [14C]  NAD+  could  be
estimated by using High Performance Liquid Chromatography (HPLC) or ethyl acetate extraction,
or  boronic  acid  resin filtration  of  the  [14C]  nicotinamide  product  followed  detection  under  the
scintillation counting (McDonagh et al., 2005). This method is certainly very useful and sensitive,
but coupled with drawback of significant health hazards, high cost and cumbersome management of
radioactive  substrates.  One  cannot  ignore  the  crucial  and  sensitive  aspect  of  waste  disposal
management that is major attribute of radioactive studies. 
There  is  a  popular  fluorescent  assay of sirtuin utilizing  fluorescent  substrates   namely 7
amino 4 methylcoumarin. This substrate conjugates to the C-terminal end of a short acetyl-lysine
containing  peptide  and  upon  deacetylation  causes  ε-amino  group  of  the  lysine  into  a  trypsin
substrate.  Subsequently,  trypsin  cleavage  releases  the  fluorophore  resulting  in  an  enhanced
fluorescence (Wegener et al., 2003). Alternatively, the Cbz-Lys(Ac)-AMC (Z-MAL) substrate can
be also employed to asses sirtuin activity by utilizing technique- Fluorescence Resonance Energy
Transfer (FRET) (Heltweg, 2003). Here the substrates used are C-terminal fluorophore and an N-
terminal quencher (Marcotte et al., 2004), and fluorescence polarization substrates with a C-terminal
fluorophore and an N-terminal biotin (Kaeberlein et al., 2005). However, there is some discrepancy
in results of SIRT1 activation by some compounds in fluorescent method with the activity measured
by non-fluorescent peptides or full length proteins (Borra et al., 2005). 
Caliper’s mobility shift assay technology (Liu et al., 2008), Enzyme Linked Immunosorbent
Assays (ELISA) (Schlicker et al., 2008) and capillary electrophoresis assays (Fan et al., 2009) are
other popular methods for sirtuin assay. Each of the above explained assays has its own advantages
and disadvantages with noticeable constraints as - unnatural fluorescent, radioactive health hazards,
difficult  to  synthesize  substrates,  additional  enzymatic  steps  for  detection  of  the  deacetylation
reaction, specialized equipment, trained technicians to undertake analysis etc. (Schuster et al., 2016).
There exists the possibility of a cutting edge and contemporary bioluminescent system of
sirtuin estimation, that hold most promising benefits of being highly quick, safe and sensitive than
any other method described above. Moreover, this technique encompasses other techniques due to
its  application  as  a  miniaturized  bio  diagnostic  and  battery  operated  portable  system.  The
bioluminescent assay is simple, doesn’t require any specialized skilled personnel to operate and is
capable of conducting high throughput screening of analytes. 
To conclude we need a take home message that what are dietary requirements to promote
sirtuin activity and what are the future possibilities with sirtuins linked with health. 
Nutrition-affected sirtuin activity
Hippocrates said few thousand years ago “let food be thy medicine”; and it holds good even
today! It is a well-known fact that diet plays a major and key role in maintaining health throughout
life. Research has investigated the possibility of consuming specific dietary components that would
aid in weight management (Pande and Srinivasan, 2012) and healthy lifespan. Pallauf et al., (2013)
have highlighted that certain foods activates sirtuin by mediating calorie restriction like effects in
the human body and they are loosely referred to as sirtfoods. These includes mainly the Asian and
Mediterranean diets that promotes using turmeric, green tea, extra virgin oil, wild leafy greens, nuts,
berries, red wine, dates, herbs etc. Sirtfoods are reported to bring about calorie restriction mediated
activation  of  sirtuin.  There  arises  a  spontaneous  question  that  how  do  they  regulate  calorie
restriction?  Do  they  express  calorie  restriction  like  effects  or  actually  help  in  reducing  calorie
intake? The answer is both of the above two. 
Polyphenols are the common bioactives in green tea, citrus fruits, richly coloured fruits and
vegetables,  red  wines  etc.  In  yeast,  resveratrol  (active  principle  of  green  tea)  express  calorie
restriction by activating sirtuin, thereby improving DNA stability and enhancing lifespan up to 70%,
and it is a proposed activator of sirtuin. Further investigation revealed that two structurally similar
compounds  namely  quercetin  and  piceatannol  stimulate  SIRT1  activity  by  five  and  eightfold,
respectively. Both quercetin and piceatannol are polyphenols biochemically  (Ferguson, 2001). The
biological effects of polyphenols are frequently attributed to antioxidant, metal-ion-chelating and/or
free-radical-scavenging activity and there is a possibility that the stimulation of SIRT1 might simply
represent the repair of oxidative or metal-ion induced damage to the recombinant protein.
 Leptin and adiponectin hormone are found to be beneficially impacted by sirtuin activity. It
is noteworthy that these hormones are key regulators of satiety and appetite by regulating activity of
hypothalamus (Hochberg and Hochberg,  2009).  Circulating leptin  levels illustrates  total  visceral
adipose tissues. As calorie restriction depletes leptin levels, it in turn enhances adiponectin levels,
which  have  been  reported  to  assert  a  cardio  protective  effect  (Ziemke  and  Mantzoros,  2010).
Lowering  of  adipose  tissue  subsequently  lowers  the  leptin/adiponectin  ratio,  favoring  insulin
sensitivity thus maintaining blood glucose level. 
Ageing is  characterized  by significant  oxidative  damage evoked by free radicals  such as
superoxide, hydrogen peroxide, peroxynitrite etc. The endogenous network of antioxidant enzymes
shields the cell against oxidative stress (Pande and Srinivasan, 2013). Ageing signifies accumulation
of damaged proteins, lipids, cells, tissues and organelles in the humans gradually progressing to
reduced antioxidant capacity and functionality of these enzymes. Consequently, there is an invariant
increased ROS production with old age  (Pérez et al.,  2009). Since calorie restriction lowers the
release of ROS in mitochondria by virtue of sirtuin activation (Sohal and Weindruch, 1996), sirtuin
brings about decrease in the detrimental effects of ageing.
 Red wine constituents (resveratrol) may positively affect both health and lifespan (Baur et
al.,  2006) due to activation of SIRT1  (Morselli  et  al.,  2010) and hence there is  a possibility  of
endothelium protection  and NF�B inhibition  which is  related  to SIRT1 induction.  Experimental
animals fed diets rich in olive oil phenolics (e.g., hydroxytyrosol) were reported to exhibit decreased
oxidative damage markers such as peroxides in several tissues  (Bayram et al., 2012; Bajoub et al.,
2016), and consumption of olive oil also promoted SIRT1 signaling (Menendez et al., 2013). 
  Several researches have observed that turmeric and soy contain active principles namely
curcumin  and  isoflavons  respectively  (Rimbach  et  al.,  2008;  Suresh  and  Srinivasan,  2010).
Curcumin has been studied to influence sirtuin activity and other transcription factors (Grabowska
et  al.,  2016)  thus  explaining  its  cardioprotective  effects  in  terms  of  lowering  Low  Density
Lipoprotein (LDL) oxidation and inhibition of platelet  aggregation.  Isoflavons also exert  SIRT1
activation  effect  (Rasbach  and  Schnellmann,  2008).  Seaweed  is  a  rich  provider  of  antioxidant
vitamins and polyunsaturated omega 3 fatty acids (Rajapakse and Kim, 2011) which may also exert
significant  cardioprotective  effect  by  stimulating  the  activity  of  sirtuins.  Hence  there  are
considerable evidences and scientific studies suggesting towards benefits of consumption of specific
diet to induce activation of sirtuins, which in turn offers health benefits and promotes well being. 
Conclusion
          Numerous molecules have been recognized as a marders of nutrition. It is generally believed
that  deacetylases  (sirtuins)  significantly influence multiple  metabolic  pathways linked to ageing,
inflammation,  ischemia,  mitochondrial alterations,  etc. towards the direction where they promote
well-being.  A nutritional  strategy  to  restore/improve  sirtuin  levels,  which  in  turn  improves  the
overall health of the subject, can reveal unexplored powerful horizons for nutritional science and
may revolutionize it to a significant extent. But this requires research to substantiate and validate the
impact of sirtuins in human subjects. And once it is validated, then nutritionists have the task to
develop standard nutritional guidelines to enhance circulating and activity levels of sirtuins in the
body. These guidelines will serve to educate common mass as to what and how much to eat so as to
improve sirtuin levels in the body, and consequently health. Coupled with this, is the milestone to
highlight the safe or optimum or beneficial activity levels of sirtuins in different tissues, thereby
identifying current or ongoing health  and nutritional  status of an individual  and devise ways of
improving it.  There is also the opportunity to develop new and low cost diagnostic  methods as
bioluminescent methods to undertake quick, economical and convenient testing of sirtuin levels in
different body tissues. 
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Table 1- The biomarkers for different nutrients and food items
Nutrient/Food Accepted biomarker
Sugar Urinary sucrose and fructose
Calcium urinary deoxypyridinoline, serum osteocalcin
Copper Serum copper,  Serum ceruloplasmin
Selenium Plasma selenium
Molybdenum Urinary sulfate and uric acid
Chromium Impaired glucose tolerance
Vitamin A Serum retinol
Whole wheat Plasma alkylresorcinol
Total fat RBC concentration of  MUFA, PUFA and SFA;  plasma
phospholipids  and cholesterol esters 
Fatty acids n-6 and n-3 PUFA in Phospholipids
Essential fatty acids Adipose α-linolenic and serum linoleic acid
Olive oil Urinary Tyrosol and hydroxytyrosol phenolic acids
Total Proteins Urinary nitrogen
Citrus Proline betaine
Garlic Urinary S-allyl-mercapturic acid
Wine Urinary or plasma Resveratrol
Sirtuin Activity Substrates Functions References
SIRT1 Deacetylase
Foxo1,  Foxo3,  Bax,  Hif-
1α,  Hif-2a,  HSF1,  Ku70,
b-catenin,  E2F1,  Myc,
STAT3,  PGC-1a,  NF-κB,
TORC2,  LXR,  FXR,
SREBP,  PER2,  CLOCK,
p53
Energy  metabolism,  stress
response,  tumor
suppression  activity,
glucose  and  fat
mobilization,  lowering
neurotoxicity
Haigis  and
Sinclair  (2010),
Li  and  Kazgan
(2011)
SIRT2 Deacetylase Tubulin, H4, Foxo3a Cell cycle Wang  et  al,
(2007)
SIRT3
Deacetylase
Oxidative phosphorylation
complex  I,  AceCS2,
LCAD,  HMG-CoA
synthase  2,  IDH2,
MnSOD, SOD2
ATP  production,  reducing
oxidative   stress,
thermogenesis,   tumor
suppression  activity  and
regulating  several
metabolic enzymes
Someya  et  al,
2010;  Qiu  et  al,
2010;  Tao  et  al,
2010)
SIRT4 ADP-ribosyl-
transferase
GDH Insulin secretion, fatty acid
oxidation
(Haigis  et  al,
2006)
SIRT5 Deacetylase CPS1 Urea cycle (Nakagawa, 2009)
SIRT6 Deacetylase/ADP-
ribosyl-transferase
H3K9,  H3K56,  CtIP,
SIRT6
DNA  sand  repair,
metabolism, inflammation
Kaidi et al, 2010)
SIRT7 Deacetylase p53 rDNA transcription mainly
regulation  of  RNA
polymerase  I  and
anticancer activity
(Ford, 2006)
Table 2- Sirtuin metabolism 
Abbreviations: p53, tumor suppressor protein 53; Foxo, forkhead box O; Bax, Bcl2 associated X
protein; Hif, hypoxia-inducible factor; HSF1, heat shock factor 1; STAT3, signal transducer and
activator of transcription 3; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator
1α; NF-κB, nuclear factor-kappa B; TORC2/CRTC2, a transcriptional coactivator for the
transcription factor CREB; LXR, liver X receptor; FXR, farnesoid X receptor; SREBP, sterol
regulatory element binding protein; PER2, period circadian protein homolog 2; H4, histone 4;
AceCS2, acetyl-CoA synthetase 2; LCAD, long-chain acyl CoA dehydrogenase; HMG-CoA
synthase 2, 3-hydroxy-3-methylglutaryl CoA synthase 2; IDH2, isocitrate dehydrogenase 2;
MnSOD, Mn-superoxide dismutase; SOD2, superoxide dismutase 2; GDH, glutamate
dehydrogenase; CPS1, carbamoyl phosphate synthetase 1; CtIP, C-terminal binding protein
interacting protein; H3K9, histone 3 acetyl-lysine 9; H3K56, histone 3 acetyl-lysine 56; CtIP, C-
terminal binding protein interacting protein.



